Phenylketonuria, Maternal

Rare Diseases
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BioMarin Pharmaceutical
1 program
PegvaliaseN/A1 trial
Active Trials
NCT05579548Recruiting50Est. Oct 2032

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BioMarin PharmaceuticalPegvaliase

Clinical Trials (1)

Total enrollment: 50 patients across 1 trials

A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding

Start: Nov 2022Est. completion: Oct 203250 patients
N/ARecruiting

Related Jobs in Rare Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 50 patients
1 companies competing in this space